US Patent 9133272 Bispecific binding agents
Patent 9133272 was granted and assigned to Amgen on September, 2015 by the United States Patent and Trademark Office.
All edits
Edits on 29 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 3 Dec, 2023
Golden AI
Edits made to:
Article (+191 characters)
Article
Patent abstract
The invention relates to bispecific anti-sclerostin/anti-DKK1 binding agents and combinations of anti-sclerostin and anti-DKK1 binding agents, and related methods of treatment.
Edits on 16 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09133272 Bispecific binding agents US Patent 9133272 Bispecific binding agents
Infobox
Patent Number
091332720
Patent Number
91332720
Edits on 26 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
091332720
Date of Patent
September 15, 2015
0Patent Application Number
134090190
Date Filed
February 29, 2012
0Official Website
Patent Primary Examiner
Edits on 8 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 3 Jan, 2022
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 09133272 Bispecific binding agents
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
09133272
Date of patent
September 15, 2015
Patent application number
13409019
Date Filed
February 29, 2012
Patent primary examiner
Find more entities like US Patent 9133272 Bispecific binding agents
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.